Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of SHR-8068 + adebrelimab + bevacizumab + TACE in unresectable hepatocellular carcinoma
CTR20262591Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing SHR-8068 + adebrelimab + bevacizumab + TACE with Placebo control + TACE (2 arms). Primary endpoint: Progression-free survival. Started Jul 2026; status: active.
02
Drugs
CS1002adebrelimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20262591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262591.